Neurocrine Biosciences (NBIX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Todd Tushla - VP, IRKyle Gano - CEOMatt Abernethy - Chief Financial OfficerEric Benevich - Chief Commercial OfficerEiry Roberts - Chief Medical OfficerPaul Matteis - Managing Director, Head of Therapeutics ResearchPhoebe Tan - Senior Biotechnology Equity Research AssociateTazeen Ahmad - MD - US Equity ResearchPhilip Nadeau - MD, Health Care – BiotechnologyBrian Abrahams - MD & Global Sector Head - Health Care R ...

Ekso Bionics (EKSO) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Greetings, and welcome to the Ekso Bionics First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Stephen Comer of Investor Relations. Thank you. You may begin. Speaker1 Thank you, operator, and good af ...

EverQuote (EVER) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and thank you for standing by. My name is Calvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the EverQuote First Quarter twenty twenty five Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer Thank you. I would now like to turn the call over to Brinley ...

Vertex Pharmaceuticals (VRTX) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good day, and welcome to the Vertex Pharmaceuticals First Quarter twenty twenty five Earnings Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please note this event is being recorded. I would now like to turn the conference over to Ms. Susie Lisa. Please go ahead, ma'am. Speaker1 Good evening, all. My name is Susie Lisa, and as the Senior Vice ...

Financial Data and Key Metrics Changes - Denny's reported Q1 domestic system-wide same restaurant sales decreased by 3% compared to the previous year, with company same restaurant sales down by 0.9% and franchise same restaurant sales down by 3.2% [16][17] - Total operating revenue for the quarter was $111.6 million, up from $110 million in the prior year quarter, driven by additional Kiki's units and higher local advertising contributions [23] - Adjusted net income per share was $0.08, with an adjusted EBITDA of $16.8 million [30] Business Line Data and Key Metrics Changes - Denny's same restaurant sales decreased by 3% in Q1, but April saw same restaurant sales approximately flat due to the successful Buy One Slam, Get One for $1 promotion [6][7] - Kiki's Breakfast Cafe achieved a same restaurant sales increase of 3.9% in Q1, significantly outperforming the BBI Family Dining Index in Florida [12][20] - Off-premise sales contributed positively, improving same restaurant sales by 1% and representing 22% of total sales [18][11] Market Data and Key Metrics Changes - California and Florida were the strongest markets for Denny's, with California outperforming the BBI Family Dining Sales Index for the fifth consecutive quarter [16] - Consumer sentiment remains negative, particularly among lower-income households, impacting overall sales performance [6][17] Company Strategy and Development Direction - The company is focusing on value-driven initiatives and promotional offers to attract customers in a challenging economic environment [5][6] - Denny's is committed to expanding Kiki's Breakfast Cafe, with plans for 12 to 20 new openings this year, and has opened six new cafes year-to-date [22][12] - The company is also enhancing its digital presence and off-premise strategies to capture a broader audience [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the second quarter, noting improvements in consumer sentiment and sales trends [31][50] - The company anticipates being in the lower half of its same restaurant sales guidance range for the year, projecting a range of negative 2% to positive 1% [31][32] - Management highlighted the importance of ongoing promotional strategies and value offerings to maintain customer engagement [39][41] Other Important Information - The company completed six remodels during the quarter, with over 50% of its company fleet remodeled under the new image [19] - Commodity costs, particularly for eggs, have significantly impacted margins, with expectations for prices to moderate in the coming months [25][27] Q&A Session Summary Question: How is the strategy of introducing new value offers shaping the outlook for the rest of the year? - Management indicated that the promotional value strategy is essential in the current environment, and they will continue to refine it while monitoring consumer needs [39][40] Question: Are there signs of improvement in consumer sentiment across different cohorts? - Management noted that all income cohorts showed improvement in April, particularly those earning above $60,000 [52] Question: What is the franchisee appetite for promotions like the BOGO offer? - Franchisees have responded positively to the BOGO promotion, which has driven traffic and improved overall sales [56][58] Question: What is the outlook for menu pricing and its impact on same-store sales? - The company expects approximately 4% to 4.5% of pricing to be implemented in 2025, with a cautious approach to future pricing adjustments based on market conditions [63][64] Question: How is the company managing the impact of new cafe openings on margins? - Management acknowledged that new cafes typically experience inefficiencies initially, but they are working to optimize operations over time [96][98] Question: What is the expected impact of egg prices on margins moving forward? - Management indicated that the worst impact from egg prices was seen in Q1, with expectations for moderation in the following quarters [100]

Financial Data and Key Metrics Changes - The company reported a total revenue growth of 18% and adjusted EBITDA growth of 32% for the first quarter [13][17] - The projects business revenue grew by 23%, while energy asset revenue increased by 31% [14][17] - The net income attributable to common shareholders was a loss of $5,500,000 or $0.10 per share [16] Business Line Data and Key Metrics Changes - The total project backlog increased by 22% to $4,900,000,000, with a contracted project backlog growing by 80% to $2,600,000,000 [17] - The energy asset operating base now stands at 742 megawatts, reflecting significant growth compared to the previous year [14] Market Data and Key Metrics Changes - The company experienced strong performance in Europe and Canada, contributing to the overall revenue growth [14] - Approximately 30% of the current total project backlog is attributed to federal government contracts, with military-related customers accounting for two-thirds [6] Company Strategy and Development Direction - The company aims to leverage federal lands for critical energy infrastructure projects, enhancing its project offerings [10] - The focus remains on diversifying energy solutions to meet the increasing demand for distributed and resilient energy systems [5][11] - The company is optimistic about capturing more infrastructure and resiliency projects as government priorities evolve [19] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the federal contracts, noting that recent cancellations have been rescoped and paused contracts have resumed [7][9] - The company anticipates continued growth in project revenue, with expectations for Q2 revenue to be in the range of $400,000,000 to $425,000,000 [18] - Management highlighted the importance of energy efficiency projects being budget-neutral, which aligns with government interests [24] Other Important Information - The company has a solid cash position of approximately $72,000,000 and total corporate debt of $270,000,000 [17] - The company is actively managing its supply chain to mitigate potential impacts from tariffs and inflation [12][41] Q&A Session Summary Question: Update on federal business visibility and contract situations - Management noted that a canceled contract has been rescoped and paused contracts have resumed, leading to a positive outlook for federal contracts [22][23] Question: Margins for Q2 and the rest of the year - Management expects gross margins for the full year to be in the range of 15.5% to 16%, despite Q1 being slightly lower due to a mix of European EPC contracts [26] Question: Impact of blackouts in Southern Europe on project opportunities - Management indicated that increasing reliance on renewable energy without adequate storage could lead to more outages, highlighting the need for distributed generation solutions [28][30] Question: Economics of projects sensitive to the Inflation Reduction Act - Management has safe harbored the ITC for many projects, minimizing short-term impacts from potential changes in the IRA [32][33] Question: Effects of reduced federal workforce on project timelines - Management has not yet seen negative impacts but acknowledged potential delays in award conversions due to administrative challenges [38][39] Question: Structure of contracts regarding tariffs - Management confirmed that new contracts include protective language against tariffs, allowing for pass-through adjustments to customers [48][50] Question: Observations on private versus public market valuations - Management noted robust private valuations for projects, despite public market fluctuations, indicating strong fundamentals in their offerings [45][46]

Castle Biosciences (CSTL) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Speaker0 Good afternoon and welcome to Castle Biosciences First Quarter twenty twenty five Conference Call. As a reminder, today's call is being recorded. We will begin today's call with opening remarks and introductions, followed by a question and answer session. I would like to turn the call over to Camilla Zuccaro, Vice President of Investor Relations and Corporate Affairs. Please go ahead. Speaker1 Thank you, operator. Good afterno ...

Financial Data and Key Metrics Changes - In Q1 2025, the company generated revenues of $738 million and diluted earnings per share of $3.26, benefiting from fleet expansion and insurance settlements [5][6] - The company received $329 million in insurance proceeds during the quarter, with an additional $227 million received shortly after [6][30] - Interest expense increased by approximately $28 million year over year, driven by a 23 basis point rise in the composite cost of funds to 4.26% [28][29] - Book value per share increased to $62.32 due to significant insurance recoveries [30] Business Line Data and Key Metrics Changes - Rental revenue rose 5% year over year to approximately $645 million, while lease yields remained flat compared to the previous year [25] - The company sold 16 aircraft for $521 million, generating $61 million in gains, representing a 13% gain on sale margin [27] - Fleet utilization remained at 100%, with the weighted average age of the fleet slightly increasing to 4.7 years [7] Market Data and Key Metrics Changes - Airlines in Asia reported strong passenger traffic and forward bookings, while North American airlines experienced softer traffic due to tariff announcements [10][11] - European airlines continued to show robust demand for aircraft, with positive earnings reported by major carriers [12][13] - The global airline fleet is expected to remain behind in replacing older aircraft due to supply constraints from manufacturers [15] Company Strategy and Development Direction - The company aims to consider a wide range of capital allocation options, including organic and inorganic growth, as well as returning capital to shareholders [22] - The company is focused on maintaining a strong liquidity position and is awaiting further insurance recoveries to enhance capital flexibility [32] - The management emphasized the importance of patience and careful capital allocation to drive long-term shareholder value [22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's prospects for 2025 and beyond, despite geopolitical and macroeconomic uncertainties [22] - The company highlighted that tariffs are the responsibility of the airline customers, and there are currently no aircraft deliveries scheduled to countries with applicable tariffs [16][50] - Management noted that the demand for aircraft remains strong globally, with no significant changes in the overall aircraft demand picture [14] Other Important Information - The company has reached its target debt-to-equity ratio, allowing for more flexibility in capital allocation [32] - The company is closely monitoring the debt capital markets during periods of volatility [22] Q&A Session Summary Question: Any real-time examples of lease extensions or order book placements post tariffs? - Management provided an example of a recent lease extension with a major airline in Asia, with rates significantly higher than previous COVID-era rates [38] Question: Should we assume the 82% recovery from Russia claims is not final? - Management stated that they are in ongoing litigation and cannot comment further on the total additional capital expected [41] Question: What are the priorities for capital allocation? - Management indicated that they are considering various options, including buybacks, M&A, and increased dividends, but no specific direction was provided [45][46] Question: Will airlines reach out for assistance regarding tariffs? - Management reiterated that airlines are responsible for tariffs and currently, there are no deliveries scheduled to countries with applicable tariffs [50] Question: Can you elaborate on organic growth opportunities? - Management expressed flexibility in considering various growth opportunities, including potential used aircraft acquisitions [58] Question: What are the expectations for net margins? - Management confirmed that there are no changes to profitability expectations for the year [72]

Oppenheimer Holdings (OPY) FY 2025 Annual General Meeting May 05, 2025 04:30 PM ET Speaker0 Hello, and welcome to the Annual Meeting of Stockholders of Oppenheimer Holdings Incorporated. During the meeting, you can submit questions or comments at any time. If you are a Class B shareholder, you may enter a question or comment at any time by clicking on the q and a icon. If you are a Class A shareholder and have a question, you may e mail that question to infopco dot com. It is now my pleasure to turn today's ...

Financial Data and Key Metrics Changes - Total revenues for Q1 2025 were $99 million, reflecting a 4% increase compared to Q1 2024 [20] - Adjusted EBITDA increased approximately 1% from $17.3 million to $17.5 million in Q1 2025 [20] - Adjusted EBITDA margin was 17.7%, relatively flat compared to the previous year [21] - Gross margins decreased to 64.2% from 64.6% year over year due to lower revenue from higher margin products [22] Business Line Data and Key Metrics Changes - Strength graft revenues grew 19% on a constant currency basis in Q1 2025 [8] - On X revenue increased by 11% year over year on a constant currency basis [11] - BioGlue revenues grew 9% on a constant currency basis [12] - Tissue processing revenues declined 23% year over year due to the backlog caused by a cybersecurity incident [12] Market Data and Key Metrics Changes - Latin America and Asia Pacific saw constant currency revenue growth of 268% and 14% respectively in Q1 2025 [13] - North America revenues declined by 6% compared to Q1 2024 [21] - EMEA revenues increased by 14% year over year [21] Company Strategy and Development Direction - The company is focused on ramping up On X supply and clearing the tissue processing backlog, with expectations to be fully caught up by the end of Q3 2025 [7][13] - The ongoing launch of AMDS in the U.S. is a key growth driver, with approximately 150 facilities actively seeking approvals [10][11] - The company aims to leverage positive clinical data to expand market share for On X valves, particularly among younger patients [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit revenue growth and twice that rate for EBITDA in the future [19][29] - The company raised its full-year 2025 revenue guidance to a constant currency growth range of 11% to 14% [24] - Management noted that the impact of the cybersecurity incident is being resolved, with expectations for a return to normalcy in operations [6][29] Other Important Information - The company incurred approximately $4.7 million in Q1 related to the cybersecurity incident, which is excluded from adjusted EBITDA [22] - The net leverage ratio improved to 4.0 from 4.5 year over year [24] - The company does not anticipate the need to raise additional capital to fund its operations in the foreseeable future [22] Q&A Session Summary Question: Contribution of AMDS to growth and onboarding of facilities - Management indicated that AMDS contributed to the strong growth but did not break out specific numbers. They are encouraged by the reception from the clinical community and the onboarding process is progressing well [36][38] Question: Expectations for tissue growth recovery - Management expects to return to mid-single-digit growth for tissue processing by the end of the year, with the backlog being cleared in Q2 and Q3 [40][42] Question: Cash flow expectations for the year - Management expects to be free cash flow positive for the year, despite Q1 being seasonally high in expenses [54][56] Question: Growth rates for On X and stent grafts - Management expects On X to continue double-digit growth and stent grafts to grow at a mid-teens rate, with AMDS expected to improve overall growth rates [64][66] Question: Timing for acquiring Endospan - The option to acquire Endospan will trigger upon FDA approval, expected in the second half of 2026, with a decision required within 90 days of approval [72][74] Question: Feedback on Nexus data and market opportunity - Management expressed optimism about the Nexus data and its potential market impact, noting that the mortality benefits could lead to increased adoption [80][82]